Optimized Posterior Left Atrial Wall Ablation Strategy for PeAF

Официальное название

Optimized Posterior Left Atrial Wall Ablation Strategy for Persistent Atrial Fibrillation: A Multicenter Large-Sample Clinical Study

Обзор

This is an open-label, multicenter, randomized parallel-controlled clinical trial. The study aims to investigate the optimal ablation method for the posterior left atrial wall in patients with persistent atrial fibrillation (PsAF).

Подробное описание

This is an open-label, multicenter, randomized parallel-controlled clinical trial. The study aims to investigate the optimal ablation method for the posterior left atrial wall in patients with persistent atrial fibrillation (PsAF).

The main content of the research includes comparing three approaches through randomization: pulmonary vein isolation (PVI) alone, PVI plus pulse field ablation (PWI), and PVI plus anatomical and potential-guided ablation, to evaluate their effects on reducing the recurrence rate of atrial fibrillation. The study is designed with three groups: the PVI-alone group, the PVI + PWI group, and the PVI plus anatomical and potential-guided ablation group.

Вмешательства

• Процедура PVI + Posterior Wall Isolation (PWI) + Electrogram Ablation (EGM)
  PVI + Posterior Wall Isolation (PWI) + Electrogram Ablation (EGM) After performing PVI, electrogram mapping of the posterior left atrial wall is conducted. Subsequently, PWI and EGM ablation are performed. In this group, multipolar mapping catheters are used for EGM mapping. Target EGMs include spatially discrete potentials (STPs), localized short cycle length potentials (SCLPs), and focal activities.
• Процедура PVI + Posterior Wall Isolation (PWI)
  After performing PVI, the mapping catheter will be placed on the posterior wall to assess electrical activity and guide ablation. A bottom linear ablation (25-40W) will be performed, connecting the lowest points beneath the lower PVs. A top linear ablation (25-40W) will be conducted at the top of the left atrium, connecting the highest points above the upper PVs. If posterior wall isolation is not achieved after completing the bottom and top lines, mapping and localization of the earliest activa
• Процедура Pulmonary Vein Isolation (PVI) alone
  The distance between the ablation lines on the posterior wall after circumferential pulmonary vein isolation should be at least 2 centimeters to limit the portion of the posterior wall within the PVI ablation zone. PVI will be confirmed by verifying entrance and exit block at the PV orifices.

Первичные конечные точки

• recurrence of atrial arrhythmias [Срок оценки: at least 12 months of follow-up, beyond the initial 3-month blanking period]

Вторичные конечные точки (12)

• no occurrence of any documented atrial fibrillation (AF) episode lasting more than 30 seconds [Срок оценки: at least 12 months of follow-up, beyond the initial 3-month blanking period]
• occurrence of any documented atrial arrhythmia lasting more than 30 seconds [Срок оценки: at least 12 months of follow-up, beyond the initial 3-month blanking period]
• the burden of atrial fibrillation at 12 months of follow-up between different study groups [Срок оценки: at least 12 months of follow-up, beyond the initial 3-month blanking period]
• no occurrence of any documented atrial arrhythmia lasting more than 30 seconds [Срок оценки: at least 12 months of follow-up, beyond the initial 3-month blanking period]
• no occurrence of any documented persistent atrial arrhythmia lasting more than 7 days [Срок оценки: at least 12 months of follow-up, beyond the initial 3-month blanking period]
• no occurrence of any documented symptomatic atrial fibrillation, flutter, or tachyarrhythmia lasting more than 30 seconds [Срок оценки: at least 12 months of follow-up, beyond the initial 3-month blanking period]
• Procedure duration / Fluoroscopy time / Radiofrequency ablation time [Срок оценки: Record the duration of the surgery, fluoroscopy time, and radiofrequency ablation time immediately after the completion of the radiofrequency ablation procedure, measured in hours.]
• Posterior wall isolation success rate (bidirectional block). [Срок оценки: Evaluate from the date of the procedure until the first documented recurrence of atrial arrhythmia, with a maximum assessment duration of 12 months.]
• Number of repeat procedures within at least 12 months of follow-up [Срок оценки: at least 12 months of follow-up, beyond the initial 3-month blanking period]
• Number of direct current (DC) cardioversions performed due to atrial fibrillation recurrence within at least 12 months of follow-up. [Срок оценки: at least 12 months of follow-up, beyond the initial 3-month blanking period]
• Use of antiarrhythmic drugs at 3 months, at the time of atrial fibrillation recurrence, and at final follow-up. [Срок оценки: Evaluate from 3 months post-procedure until the first documented recurrence of atrial fibrillation, with a maximum assessment duration of 12 months]
• Perioperative complications [Срок оценки: Perioperative period]

Критерии участия

Критерии включения

• Patients aged ≥18 years.
• Patients undergoing their first ablation procedure for PsAF.
• Persistent atrial fibrillation (AF): Defined as episodes lasting ≥7 days and ≤3 years (including those requiring pharmacological or electrical cardioversion ≥7 days).
• Atrial fibrillation symptoms that are intolerant to at least one antiarrhythmic drug (AAD).
• At least one episode of PsAF must have been documented within the last 2 years by methods such as ECG, Holter monitoring, loop recorder, telemetry, remote telemonitoring (TTM), or implanted devices prior to enrollment in this study.
• Patients must be capable and willing to provide written informed consent to participate in the study.
• Patients must be willing and able to comply with all study follow-up requirements.

Критерии исключения

• Paroxysmal AF: Defined as episodes lasting \<7 days (or resolved with medication/electrical cardioversion within \<7 days).
• Patients with long-standing persistent AF: Defined as persistent AF lasting \>3 years.
• Patients who have never attempted/pursued cardiac rhythm restoration or sinus rhythm.
• Contraindication to systemic anticoagulation.
• Pregnancy.
• Advanced renal or hepatic failure.
• Severe valvular heart disease or cyanotic congenital heart disease.
• Hypertrophic cardiomyopathy.

Критерии приведены из реестра в оригинале (на английском). Окончательную оценку соответствия проводит исследовательский центр.

Здоровые добровольцы: Нет

Дизайн исследования

Распределение

Рандомизированное

Модель

Параллельные группы

Маскирование

Открытое

Основная цель

Лечение

Центры проведения

Список центров уточняется — проверьте первичный протокол.

Идентификаторы

NCT: NCT06633523 · OPLAWAS-AF

Первоисточники (государственные реестры)

• ClinicalTrials.gov (NIH, США)

Открыть это исследование на ClinicalTrials.gov ↗